ACR Appropriateness Criteria® diffuse large B-cell lymphoma Journal Article
| Authors: | Dabaja, B. S.; Advani, R.; Hodgson, D. C.; Dhakal, S.; Flowers, C. R.; Ha, C. S.; Hoppe, B. S.; Mendenhall, N. P.; Metzger, M. L.; Plastaras, J. P.; Roberts, K. B.; Shapiro, R.; Smith, S. M.; Terezakis, S. A.; Winkfield, K. M.; Younes, A.; Constine, L. S. |
| Article Title: | ACR Appropriateness Criteria® diffuse large B-cell lymphoma |
| Abstract: | The management of diffuse large B-cell lymphoma depends on the initial diagnosis including molecular and immunophenotypic characteristics, Ann Arbor staging, and International Prognostic Index (IPI score). Treatment approaches with different chemotherapy regimens used is discussed in detail. The role of radiation as a consolidation is discussed including: (1) the prerituximab randomized trials that challenged the role of radiation, (2) recent prospective studies (UNFOLDER/RICOVER-60), and (3) retrospective studies; the last 2 showed a potential benefit of radiation both for early and advanced stage. The document also discusses the role of positron emission tomography/computed tomography for predicting outcome and potentially guiding therapy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peerreviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. © 2013 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | primary tumor; prednisone; intensity modulated radiation therapy; doxorubicin; advanced cancer; cancer combination chemotherapy; treatment duration; radiation dose; cytarabine; methotrexate; rituximab; cancer staging; drug megadose; outcome assessment; cancer diagnosis; prospective study; gene expression profiling; radiation; etoposide; evidence based practice; cyclophosphamide; dexamethasone; vincristine; practice guideline; retrospective study; lumbar puncture; peer review; bone marrow biopsy; non-hodgkin's lymphoma; folinic acid; lymphoma; computer assisted emission tomography; bleomycin; vindesine; immunophenotyping; large cell lymphoma; blood cell count; mediastinum tumor; randomized controlled trial (topic); phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); appropriateness criteria; proton therapy; large b-cell lymphoma; four dimensional computed tomography; human; article; primary mediastinal lymphoma |
| Journal Title: | American Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 |
| ISSN: | 0277-3732 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2015-12-01 |
| Start Page: | 610 |
| End Page: | 620 |
| Language: | English |
| DOI: | 10.1097/COC.0000000000000215 |
| PROVIDER: | scopus |
| PUBMED: | 26583344 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 7 January 2016 -- 610 -- Source: Scopus |
